Founder/President & CEO

Hugh Narciso has more than 25 years of medical-device and pharmaceutical development experience with an emphasis on establishing and building venture-funded start-up companies. Prior to founding BAROnova in 2006, he held senior executive positions or served on the board of directors at a variety of companies including Leptos Biomedical, Inc. (COO), Lambda Pharmaceuticals (board member), Corvascular Surgical Systems, Inc. (COO/VP, Research and Development), and Miravant Medical Technologies (VP, Product Development). Mr. Narciso is a named inventor on more than 30 U.S. patents and on a comparable number of international patents.


Vice President, Clinical Affairs
Dr. Cunningham brings with her a wealth of experience in leading clinical programs. 
Before joining BAROnova, Inc., she served as the Vice President of Clinical Affairs at Guided Delivery Systems, Inc., a structural heart medical device company developing 
a Class III cardiac implant. Prior to that, she held a variety of clinical leadership positions including Medical Director and Vice President of Clinical Affairs at TriReme Medical, Inc., and Medical Director and Vice President of Clinical Research and Education at VNUS Medical Technologies, Inc., (acquired by Covidien). She was also previously an 
assistant professor at Loyola University of Chicago and a practicing vascular surgeon 
in Shanghai, China.


Vice President, Research and Development 

Kobi Iki has more than 20 years of experience in the medical-device industry directing research programs in oncology, cardiovascular, orthopedics and obesity. Before joining BAROnova, he served as the Vice President of Research for Leptos Biomedical, a company developing a neuromodulation therapy for obesity. Prior to that, Mr. Iki held various management and senior executive positions of increasing responsibility at Vascular Architects, Smith + Nephew Endoscopy/Oratec Interventions, Corvasular and Miravant Medical Technologies.